Catalog No.
FHJ08310
Species reactivity
Human
Host species
Mouse
Isotype
IgG1, kappa
Clonality
Monoclonal
Conjugation
Unconjugated
Applications
FCM
Target
Chondroitin sulfate proteoglycan 4, CSPG4, Chondroitin sulfate proteoglycan NG2, MCSP, Melanoma chondroitin sulfate proteoglycan, Melanoma-associated chondroitin sulfate proteoglycan
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q6UVK1
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
SAA0155
Note
For research use only.
Photoimmunotheranostic agents for triple-negative breast cancer diagnosis and therapy that can be activated on demand., PMID:27448975
Roles of chondroitin sulfate proteoglycan 4 in fibrogenic/adipogenic differentiation in skeletal muscle tissues., PMID:27582000
Isolating subpopulations of human epidermal basal cells based on polyclonal serum against trypsin-resistant CSPG4 epitopes., PMID:28011196
Development and validation of a cell-based fluorescent method for measuring antibody affinity., PMID:28024998
Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy., PMID:28287848
CSPG4: A Target for Selective Delivery of Human Cytolytic Fusion Proteins and TRAIL., PMID:28657611
Functional defects in Clostridium difficile TcdB toxin uptake identify CSPG4 receptor-binding determinants., PMID:28842504
Selection of novel affinity-matured human chondroitin sulfate proteoglycan 4 antibody fragments by yeast display., PMID:28981720
Human recombinant Fab fragment from combinatorial libraries of a B-cell lymphoma patient recognizes core protein of chondroitin sulphate proteoglycan 4., PMID:29036679
Effects of chondroitin sulfate proteoglycan 4 (NG2/CSPG4) on soft-tissue sarcoma growth depend on tumor developmental stage., PMID:29196603
Resident cell lineages are preserved in pulmonary vascular remodeling., PMID:29359814
Chondroitin Sulfate Proteoglycan 4 and Its Potential As an Antibody Immunotherapy Target across Different Tumor Types., PMID:29375561
212Pb-Labeled Antibody 225.28 Targeted to Chondroitin Sulfate Proteoglycan 4 for Triple-Negative Breast Cancer Therapy in Mouse Models., PMID:29561763
Enhanced targeting of triple-negative breast carcinoma and malignant melanoma by photochemical internalization of CSPG4-targeting immunotoxins., PMID:29565434
Blood-brain barrier-associated pericytes internalize and clear aggregated amyloid-β42 by LRP1-dependent apolipoprotein E isoform-specific mechanism., PMID:30340601
Synergistic antitumor effects of 9.2.27-PE38KDEL and ABT-737 in primary and metastatic brain tumors., PMID:30625226
Mesenchymal stromal cells for bone sarcoma treatment: Roadmap to clinical practice., PMID:30956944
Bispecific Antibody Approach for Improved Melanoma-Selective PD-L1 Immune Checkpoint Blockade., PMID:31128201
Identification of CSPG4 as a promising target for translational combinatorial approaches in osteosarcoma., PMID:31217827
Proteoglycans and glycosaminoglycans as regulators of cancer stem cell function and therapeutic resistance., PMID:31230410
Selection and characterization of ultrahigh potency designed ankyrin repeat protein inhibitors of C. difficile toxin B., PMID:31233493
Designed Ankyrin Repeat Protein (DARPin) Neutralizers of TcdB from Clostridium difficile Ribotype 027., PMID:31578248
In vivo safety profile of a CSPG4-directed IgE antibody in an immunocompetent rat model., PMID:31769737
A Novel Antibody-Drug Conjugate (ADC) Delivering a DNA Mono-Alkylating Payload to Chondroitin Sulfate Proteoglycan (CSPG4)-Expressing Melanoma., PMID:32331483
Chondroitin Sulphate Proteoglycan 4 (NG2/CSPG4) Localization in Low- and High-Grade Gliomas., PMID:32599896
Oligodendrocyte Lineage Marker Expression in eGFP-GFAP Transgenic Mice., PMID:33346907
BNIP3L-mediated mitophagy is required for mitochondrial remodeling during the differentiation of optic nerve oligodendrocytes., PMID:33404293
Proteomic profile of melanoma cell-derived small extracellular vesicles in patients' plasma: a potential correlate of melanoma progression., PMID:33613873
Immunoaffinity-Based Isolation of Melanoma Cell-Derived and T Cell-Derived Exosomes from Plasma of Melanoma Patients., PMID:33704724
Structural basis for CSPG4 as a receptor for TcdB and a therapeutic target in Clostridioides difficile infection., PMID:34145250
A chondroitin sulfate proteoglycan 4‑specific monoclonal antibody inhibits melanoma cell invasion in a spheroid model., PMID:34318902
In vivo trafficking of a tumor-targeting IgE antibody: molecular imaging demonstrates rapid hepatobiliary clearance compared to IgG counterpart., PMID:34513315
Receptor binding mechanisms of Clostridioides difficile toxin B and implications for therapeutics development., PMID:34862749
Chondroitin sulfate proteoglycan 4, a targetable oncoantigen that promotes ovarian cancer growth, invasion, cisplatin resistance and spheroid formation., PMID:34942534
A proof-of-concept study on the use of a fluorescein-based 18F-tracer for pretargeted PET., PMID:35239034
Antigen mimicry as an effective strategy to induce CSPG4-targeted immunity in dogs with oral melanoma: a veterinary trial., PMID:35580930
Immunotherapeutic Targeting of NG2/CSPG4 in Solid Organ Cancers., PMID:35891187
Identification of Novel Retinal Pericyte-Targeting rAAV Vectors Through Directed Evolution., PMID:36018583
Chondroitin sulfate proteoglycan 4 expression in chondrosarcoma: A potential target for antibody-based immunotherapy., PMID:36110930
The Potential of Antibody Technology and Silver Nanoparticles for Enhancing Photodynamic Therapy for Melanoma., PMID:36140259
Generation and Characterization of Native and Sialic Acid-Deficient IgE., PMID:36362241
The role of pericytes on the efficacy of bevacizumab in colorectal cancer., PMID:36422502
VT68.2: An Antibody to Chondroitin Sulfate Proteoglycan 4 (CSPG4) Displays Reactivity against a Tumor-Associated Carbohydrate Antigen., PMID:36768830
Anti-cancer pro-inflammatory effects of an IgE antibody targeting the melanoma-associated antigen chondroitin sulfate proteoglycan 4., PMID:37185332
Bispecific antibodies redirect synthetic agonistic receptor modified T cells against melanoma., PMID:37208128
CSPG4 as a target for the specific killing of triple-negative breast cancer cells by a recombinant SNAP-tag-based antibody-auristatin F drug conjugate., PMID:37432459
MiR126-targeted-nanoparticles combined with PI3K/AKT inhibitor as a new strategy to overcome melanoma resistance., PMID:37990493
Chondroitin sulfate proteoglycan 4: An attractive target for antibody-based immunotherapy., PMID:38735753
CSPG4-targeting CAR-macrophages inhibit melanoma growth., PMID:38895447
Chondroitin Sulfate Proteoglycan 4 (CSPG4) as an Emerging Target for Immunotherapy to Treat Melanoma., PMID:39409881
For research use only. Not for human or drug use.
